Idiopathic osteonecrosis, hypofibrinolysis, high plasminogen activator inhibitor, high lipoprotein(a), and therapy with stanozolol
- 1 April 1995
- journal article
- case report
- Published by Wiley in American Journal of Hematology
- Vol. 48 (4) , 213-220
- https://doi.org/10.1002/ajh.2830480402
Abstract
In five patients with idiopathic osteonecrosis (ON) of the hip, four having hypofibrinolysis mediated by high plasminogen activator inhibitor (PAI‐Fx), and one with high Lp(a), our specific aim was to determine whether therapy (Rx) with the anabolic‐androgenic steroid, Stanozolol(6 mg/day), would normalize PAI‐Fx and Lp(a) and thus potentially ameliorate ON. Prior to Rx, none of the four patients with high PAI‐Fx could normally elevate tissue plasminogen activator (tPA‐Fx) after 10 min venous occlusion at 100 mm Hg. After 12‐18 weeks on Rx, PAI‐Fx and stimulated tPA‐Fx normalized in all four patients. Prior to Rx, mean (SD) stimulated tPA‐Fx was low, 0.4 ± 0.3 IU/ml (lower limit of normal 2.28 IU/ml). On Rx, stimulated tPA‐Fx normalized, rising to 2.83 ± 1.9 IU/ml, P = 0.004. Prior to Rx, mean (SD) basal PAI‐Fx was high, 99 ± 68 (upper limit of normal 26.9 U/ml), and fell on Rx to 22.5 ± 22, P = 0.004. In two of the five patients normalization of hypofibrinolysis or high Lp(a) was accompanied by major symptomatic improvement. Prior to Rx, and 2 years after onset of unilateral hip pain, one of the four patients with high PAI‐Fx and low stimulated tPA‐Fx could walk only one block painfully. After 8 weeks on Stanozolol Rx, and continuing through 54 weeks on Rx, he walked 2 miles per day without pain, despite radiographic progression of ON. In three of the four patients with high PAI and with osteonecrosis present 0.3, 2, and 6 years prior to Stanozolol Rx, there was no clinical improvement after 14‐156 weeks of Rx despite normalization of stimulated tPA‐Fx and PAI‐Fx. The fifth patient, 1 month after onset of disabling hip pain, had normal PAI‐Fx but high Lp(a) (27 mg/dl), and MRI evidence of bone marrow edema (“transient osteoporosis”). After 3 weeks on Rx, Lp(a) normalized (14 mg/dl) and there was marked amelioration of symptoms. For the subsequent 11 weeks on Rx, this patient's Lp(a) was 5 mg/dl, and he became totally asymptomatic and remains asymptomatic 14 months later. We speculate that when ON is diagnosed prior to segmental collapse of the femoral head, it may be possible to reverse hypofibrinolysis, and/or to arrest the progression of ON. We postulate that high PAI or high Lp(a) lead to inadequate lysis of venous thrombi in bone, impaired bone venous circulation, venous hypertension of bone, and subsequent, potentially reversible development of ON.Keywords
This publication has 36 references indexed in Scilit:
- Nontraumatic Avascular Necrosis of the Femoral HeadPublished by Wolters Kluwer Health ,1992
- EFFICACY OF FIBRINOLYTlC ENHANCEMENT WITH STANOZOLOL IN THE TREATMENT OF VENOUS INSUFFICIENCYAnz Journal of Surgery, 1991
- Fibrinolytic Enhancement with Stanozolol Fails to Improve Symptoms and Signs in Patients with Post-surgical Back PainScandinavian Journal of Rheumatology, 1991
- Making Core Decompression WorkPublished by Wolters Kluwer Health ,1990
- Capacitive Coupling as an Adjunctive Treatment for Avascular NecrosisPublished by Wolters Kluwer Health ,1990
- Osteonecrosis of the Femoral HeadPublished by Wolters Kluwer Health ,1989
- A Diagnostic Algorithm for Osteonecrosis of the Femoral HeadClinical Orthopaedics and Related Research, 1989
- A Microangiographic Study of Idiopathic Osteonecrosis of the Femoral HeadPublished by Wolters Kluwer Health ,1989
- Multimodality Approach to Osteonecrosis of the Femoral HeadPublished by Wolters Kluwer Health ,1989
- Osteonecrosis of the Femoral HeadPublished by Wolters Kluwer Health ,1988